Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug

ABSTRACT

Novel methods for delivering a drug to hospital patients for short-term in-hospital use while minimizing long-term use of the drug. Embodiments are provided in which hospitals are identified which may be eligible to treat patients, for example, perform certain types of surgery, and which have measures in place to limit use of the drug to short-term use. The identified hospitals are preferably registered in a storage medium, including computer readable storage media, and may be authorized to receive the shipments of the drug. The received drug may then be dispensed to the patient.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.12/467,016, filed May 15, 2009, now allowed, which claims the benefit ofU.S. Provisional Application Ser. No. 61/054,016, filed May 16, 2008,the disclosure of each of which is hereby incorporated herein byreference in its entirety.

FIELD OF THE INVENTION

The present invention relates to novel methods for delivering drugs tohospital patients. More particularly, the present invention relates tonovel methods for delivering drugs to hospital patients for short-termuse while minimizing long-term use of the drugs.

BACKGROUND OF THE INVENTION

In the course of an examination of a patient by a health carepractitioner, including patients suffering from one or more diseasesand/or disorders such as, for example, one or more disorders ordysfunctions of the gastrointestinal system, the health carepractitioner may determine that the patient's condition may be improvedby the administration of a drug, such as a drug that may prevent and/oralleviate disorders or dysfunctions of the gastrointestinal system. Inconnection with the health care practitioner's diagnosis of the patient,and the identification of one or more courses of treatment that mayaddress the patient's condition, including the administration of one ormore drugs, it may also be necessary to consider the potential for thecourse of treatment to produce undesired observed effects in thepatient. For example, a drug may have desirable curative or ameliorativeproperties for a particular disease or disorder, and thus may beadvantageously prescribed to the patient to address the patient'smedical needs. However, in addition to the drug's curative orameliorative properties, the possible observation of one or more adverseevents may also be associated with the drug. These observed adverseevents may occur, for example, when the drug is administered at higherdoses, and/or when the drug is administered for longer periods of time.Generally speaking, there is a continuous balance that a health carepractitioner seeks to achieve between administering a drug in asufficient dosage, at sufficient frequencies, and for a sufficientlength of time to obtain the desired beneficial effects, while at thesame time avoiding the administration of the drug in excessive dosages,too frequently, or for too long a period of time which may result in theobservation of one or more undesired adverse events.

For certain drugs, curative or ameliorative properties may be realizedwhen they are administered to patients for shorter periods of time,while a risk of adverse events may be observed when the drug isadministered for longer periods of time. Health care practitioners maybe therefore faced with the difficult task of ensuring that a particulardrug is administered to a patient in a hospital environment, oradministered for a desired period of time as in the case, for example ofshort-term use, while minimizing or avoiding the administration of thedrug in an undesired environment, such as outside of the hospital, orfor undesired periods of time as in the case, for example, of long-termuse.

To avoid the use of drugs in a manner that may elicit the undesiredobservation of adverse events, it is generally necessary that the healthcare practitioners also be educated regarding the potential for suchobserved adverse events. It may also be necessary to prevent health carepractitioners who are not educated regarding a drug's potential to causeobserved adverse events from administering the drug to patients, or fromgaining access to the drug.

Accordingly, there is a need in the medical community for improvedmethods that provide the necessary checks and controls to ensure thatdrugs are administered to patients for the appropriate period of time,in the appropriate environment, and at the proper frequency and dosages.The present invention is directed to these, as well as other importantends.

SUMMARY OF THE INVENTION

The present invention is directed to methods for the delivery topatients, particularly hospital patients, of drugs, especially drugswhose use is preferably curtailed or restricted to short-term use inhospitals.

Specifically, in one embodiment of the invention, there are providedmethods for delivering drugs to hospital patients for short-term usewhile minimizing long-term use of the drugs, wherein the methodscomprise:

(a) identifying hospitals which may be eligible to dispense the drug;

(b) providing the hospitals with literature regarding use of the drug;

(c) identifying a subpopulation of the hospitals which treat thepatients and which have measures in place to limit use of the drug toshort-term use;

(d) registering the subpopulation in a storage medium;

(e) authorizing the subpopulation to receive shipment of the drug; and

(f) dispensing the drug to the patients in the subpopulation forshort-term use.

The methods described herein provide novel and effective means fordelivering, controlling and authorizing the distribution andadministration of drugs to patients that may benefit from the use of thedrug. The methods of the present invention include a variety of checksand controls which ensure that the drug is used in hospitals forshort-term periods, and which minimize long-term use of the drug.Distribution of the drug to hospitals that may not be eligible toreceive the drug may be advantageously prevented with the presentmethods. Distribution of the drug to patients who are not hospitalpatients may also be advantageously prevented. In the case of drugswhose long-term use is associated with the observation of adverseevents, the present methods may be particularly beneficial andadvantageous, as they may be useful in minimizing and even in certaincircumstances avoiding the occurrence of such observed adverse events.

These and other aspects of the invention will become more apparent fromthe following detailed description.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is generally directed to methods for the deliveryof drugs to patients, particularly hospital patients, for short-termuse, while minimizing long term use of the drug. The term “drug”, asused herein, refers to any substance which is intended for use in thediagnosis, cure, mitigation, treatment or prevention of disease, or toaffect the structure or function of the body. The term “patient”, asused herein, refers to animals, including mammals, preferably humans.The methods of the present invention offer a variety of checks andbalances that may be employed to tightly regulate and control thedelivery of drugs to hospitals and the administration of drugs tohospital patients. The present methods may be advantageously used todeliver and administer drugs to patients within the confines of thehospital, and thereby minimize or avoid the unauthorized use oradministration of the drug as may be the case, for example, outside thetightly controlled and monitored environment of a hospital. Thus, themethods described herein are particularly useful for delivering drugs tohospital inpatients or hospitalized patients. The term “hospitalinpatient”, as used herein, refer to a hospitalized patient, i.e., apatient whose care or treatment is performed in a hospital. In preferredembodiments, the care or treatment of a hospital inpatient may require apatient's stay in the hospital of at least about one day. In certainembodiments, the patient may be required to stay in the hospital for aperiod of from about 1 day to about 10 days (and all combinations andsubcombinations of ranges of days and specific numbers of days therein).More preferably, the patient may be required to stay in the hospital fora period of from about 2 or 3 days to about 7 days.

The present methods advantageously enable a hospital to deliver drugs tohospital patients while minimizing long-term use of the drug. The term“minimize”, as used in reference to the long-term use of a drug,generally means that there is an avoidance rate of using the druglong-term of greater than about 50%. Preferably, the avoidance rate isgreater than about 55%, with an avoidance rate of greater than about 60%being more preferred. Even more preferably, the avoidance rate isgreater than about 65%, with an avoidance rate of greater than about 70%being still more preferred. Yet more preferably, the avoidance rate isgreater than about 75%, with an avoidance rate of greater than about 80%being still more preferred. In even more preferred embodiments, theavoidance rate is greater than about 85%, with an avoidance rate ofgreater than about 90% being yet more preferred. Still more preferably,the avoidance rate is greater than about 95%. In particularly preferredembodiments, a drug may be delivered to hospital patients withsubstantially no long-term use (i.e., nearly or up to a 100% avoidancerate).

The methods of the present invention may be particularly useful for thedelivery of drugs whose long-term use may be associated with theobservation of one or more adverse events. Thus, the methods of thepresent invention may be used to minimize the occurrence of observedadverse events. The term “minimize”, as used in reference to theobservation of adverse events that may be associated with the long-termuse of a drug, generally means that there is an avoidance rate inobserving adverse events of greater than about 50%. Preferably, theavoidance rate is greater than about 55%, with an avoidance rate ofgreater than about 60% being more preferred. Even more preferably, theavoidance rate is greater than about 65%, with an avoidance rate ofgreater than about 70% being still more preferred. Yet more preferably,the avoidance rate is greater than about 75%, with an avoidance rate ofgreater than about 80% being still more preferred. In even morepreferred embodiments, the avoidance rate is greater than about 85%,with an avoidance rate of greater than about 90% being yet morepreferred. Still more preferably, the avoidance rate is greater thanabout 95%. In particularly preferred embodiments, a drug may bedelivered to hospital patients with substantially no observation ofadverse events (i.e., nearly or up to a 100% avoidance rate).

The drug delivery methods of the present invention preferably involve,inter alia, the identification of hospitals that may be eligible todispense the drug. In certain preferred aspects of the presentinvention, the term “dispense” may refer to filling prescriptions orphysician orders by pharmacies, particularly hospital pharmacies, andthe distribution of the drug by the pharmacies to healthcarepractitioners within the hospital for administration to the patient.Exemplary healthcare practitioners include, for example, surgeons,nurses, anesthesiologists, certified nurse anesthetists, pharmacists andthe like. In certain other preferred aspects of the invention, the term“dispense” may refer to the administration of the drug by a healthcarepractitioner to the patient which includes, for example, oral orparenteral administration depending, for example, on the particular formof the involved drug.

In preferred embodiments of the invention, hospitals that may beeligible to dispense the drug include, for example, hospitals that maybe competent to perform certain types of surgery and/or hospitals thatare acute care hospitals. The term “surgery”, as used herein, refers toany methodical action of the hand, or of the hand with instruments, on apatient, to produce a curative or remedial effect, and includes, forexample, abdominal surgery. The term “abdominal surgery”, as usedherein, broadly refers to surgical procedures that involve opening theabdomen such as, for example, laparotomies, including bowel resectionsurgery, Caesarian births, and sterilization procedures. The term “acutecare hospital”, as used herein, refers to hospitals that are capable oftreating patients for a brief but severe episode of illness, disease ordisorder. Acute care hospitals typically seek to discharge the patientas soon as the patient is deemed healthy and stable, often withappropriate discharge instructions. In preferred embodiments of theinvention, hospital patients for whom the present drug delivery methodsmay be employed are acute care patients including, for example, surgerypatients, with abdominal surgery patients being preferred. Accordingly,eligible hospitals are preferably those which have health carepractitioners that are competent to perform abdominal surgery. Inpreferred embodiments, the hospitals involved in the methods describedherein are competent to perform bowel resection surgery, especiallybowel resection surgery in which the two remaining ends of the bowel aresewn, stapled, or both sewn and stapled together (i.e., bowel resectionsurgery involving intestinal anastomosis).

The methods of the present invention may be employed to deliver a widevariety of drugs to patients, depending on the involved illness,disease, or disorder. Drugs delivered to patients using the methodsdescribed herein are preferably drugs that are only used for limitedperiods of time (i.e., drugs that are used short-term), and whoseextended use (i.e., long-term use) is preferably avoided. Accordingly,the methods of the present invention are particularly advantageous fordelivering drugs to patients whose illness, disease or disorder istypically of short duration, and who would therefore be prescribed oneor more drugs to treat the illness, disease or disorder for a shortperiod of time, but whose disease or disorder may recur or continuebeyond the short period of time.

In preferred embodiments, the term “short-term use”, as used herein, mayrefer to the administration to a patient of no more than about 20 dosesof the drug. Accordingly, the term “long-term use”, as used herein, mayrefer to the administration to a patient of more than about 20 doses ofthe drug. The term “dose”, as used herein, refers to physically discreteunits suited as unitary dosages for ingestion by the particular patientto be treated. Each unit may contain a predetermined quantity of one ormore active ingredients, calculated to produce the desired therapeuticeffect, in association with a suitable pharmaceutical carrier. Inpreferred embodiments, the patient may receive no more than about 17doses of the drug, with no more than about 15 doses of the drug beingeven more preferred. More preferably, the patient may receive no morethan about 12 doses of the drug, with no more than about 10 doses of thedrug being even more preferred. Still more preferably, the patient mayreceive no more than about 8 doses of the drug, with no more than about6 doses of the drug being yet more preferred. In certain preferredembodiments, the patient may receive no more than about 4 doses of thedrug including, for example, no more than about 3 doses, no more thanabout 2 doses or no more than about 1 dose of the drug.

In alternate preferred embodiments, the patient may be administered atotal of from about 10 to about 20 doses of the drug (and allcombinations and subcombinations of ranges of doses and specific numbersof doses therein). More preferably, the patient may receive a total offrom about 14 to about 16 doses of the drug, with a total of about 15doses being even more preferred.

In still other preferred embodiments, the patient may be administered atotal of from about 1 to about 12 doses of the drug (and allcombinations and subcombinations of ranges of doses and specific numbersof doses therein). More preferably, the patient may receive a total offrom about 2 to about 10 doses of the drug, with a total of from about 4to about 8 doses being even more preferred. Still more preferably, thepatient may receive a total of about 6 or about 7 doses of the drug.

In embodiments of the present invention in which the patient is asurgery patient, for example, an abdominal surgery patient, the patientmay advantageously be administered the drug prior to surgery, aftersurgery, or both prior to and after surgery. Accordingly, in the contextof the present methods, the drug may preferably be delivered to thepatient prior to surgery, after surgery, or both prior to and aftersurgery. In embodiments involving surgery patients, the term “short-termuse” may refer to the administration to a patient of the drug for nomore than about 10 days after surgery. Accordingly, the term “long-termuse”, as used herein in reference to surgery patients, may refer to theadministration to a patient of the drug for more than about 10 daysafter surgery. Preferably, the patient may be administered the drug forno more than about 8 days after surgery, with the patient beingadministered the drug for no more than about 7 days after surgery beingmore preferred. Even more preferably, the patient may be administeredthe drug for no more than about 6 days after surgery, with the patientbeing administered the drug for no more than about 5 days after surgerybeing still more preferred. Yet more preferably, the patient may beadministered the drug for no more than about 4 days after surgery, withthe patient being administered the drug for no more than about 3 daysafter surgery being even more preferred. In certain particularlypreferred embodiments, the patient may be administered the drug for nomore than about 2 days after surgery or no more than about 1 day aftersurgery.

In alternate preferred embodiments, the drug may be administered to thepatient for about 5 to about 10 days after surgery (and all combinationsand subcombinations of ranges of days and specific numbers of daystherein). More preferably, the patient may be administered the drug forabout 6 to about 8 days after surgery, with the patient beingadministered the drug for about 7 days after surgery being even morepreferred.

In still other preferred embodiments, the drug may be administered tothe patient for about 1 to about 5 days after surgery (and allcombinations and subcombinations of ranges of days and specific numbersof days therein). More preferably, the patient may be administered thedrug for more than about 1 day to about 4 days after surgery, with thepatient being administered the drug for about 2 days or about 3 daysafter surgery being even more preferred.

In embodiments of the invention, including embodiments involving surgerypatients, such as abdominal surgery patients, the drug may preferably beadministered to the patient from about once a day after surgery to aboutthree times a day after surgery. More preferably, the drug may beadministered to the patient about twice a day after surgery. Also inembodiments involving surgery patients, including abdominal surgerypatients, a total of from about 10 to about 20 doses of the drug maypreferably be administered to the patient after surgery (and allcombinations and subcombinations of ranges of doses and specific dosestherein). More preferably, the patient may be administered a total offrom about 12 to about 15 doses of the drug after surgery, with a totalof about 14 doses of the drug being administered after surgery beingeven more preferred.

In alternate embodiments of the invention, including embodimentsinvolving surgery patients, such as abdominal surgery patients, a totalof from about 1 to about 12 doses of the drug may preferably beadministered to the patient after surgery (and all combinations andsubcombinations of ranges of doses and specific doses therein). Morepreferably, the patient may be administered a total of from about 3 toabout 10 doses of the drug after surgery, with a total of about 5 toabout 8 doses of the drug being administered after surgery being evenmore preferred. Still more preferably, the patient may be administeredabout 6 or about 7 doses of the drug after surgery.

In embodiments involving surgery patients, including abdominal surgerypatients, the term “short-term use” may refer to the administration ofthe drug to the patient for less than about 1 day to about 5 days priorto surgery (and all combinations and subcombinations of ranges of daysand specific numbers of days therein). Accordingly, in embodimentsinvolving surgery patients, the term “long-term use” may refer to theadministration to a patient of the drug for more than about 5 daysbefore surgery. Preferably, the patient may be administered the drug forless than about 1 day to about 2 days prior to surgery, with the patientbeing administered the drug for less than about 1 day to about 1 dayprior to surgery being more preferred.

The term “less than about 1 day” may refer to the administration of thedrug to the patient from about 1 minute to less than about 24 hoursprior to surgery (and all combinations and subcombinations of ranges oftime and specific values of time therein). Preferably, the patient maybe administered the drug from about 15 minutes to about 12 hours priorto surgery, with from about 30 minutes to about 5 hours being morepreferred.

In alternate preferred embodiments, the term “short-term use” may referto the administration of about 0 to about 5 doses of the drug prior tosurgery (and all combinations and subcombinations of ranges of doses andspecific doses therein). Accordingly, in embodiments involving surgerypatients, the term “long-term use” may refer to the administration to apatient of more than about 5 doses of the drug prior to surgery. Morepreferably, the patient may be administered about 1 to about 3 doses ofthe drug prior to surgery, with about 1 dose of the drug beingadministered prior to surgery being even more preferred.

In accordance with embodiments of the present invention, the methodsdescribed herein may be particularly useful for delivering drugs topatients suffering from gastrointestinal dysfunction. The term“gastrointestinal dysfunction”, as used herein, refers to a variety ofdisorders of the gastrointestinal system including, for example,disorders of the gastrointestinal system that may be associated withopioids, including exogenous and/or endogenous opioids, gastrointestinaldisorders due to abdominal injury and/or surgery, childbirth, andsterilization procedures, and the like. The present methods are alsouseful for delivering drugs to patients who may be expected to developgastrointestinal dysfunction. For example, patients who requireabdominal surgery such as, for example, bowel resection surgery, may beexpected to develop gastrointestinal dysfunction. Thus, the methodsdescribed herein may be advantageously used in the prevention,inhibition and/or treatment of gastrointestinal dysfunction. Examples ofgastrointestinal dysfunction that may be prevented, inhibited and/ortreated with the methods of the present invention include, for example,opioid-induced constipation (OIC), opioid-induced bowel dysfunction(OBD), ileus, including postpartum ileus and postsurgical ileus,idiopathic constipation, irritable bowel syndrome, and variouscombinations of two or more of these disorders. In preferredembodiments, the present methods may be used for preventing, inhibitingand/or treating ileus.

Mu opioid antagonist compounds, and particularly peripherally-acting muopioid antagonist compounds that do not substantially cross theblood-brain barrier into the CNS including, for example, alvimopan andN-methylnaltrexone, are known in the literature as being useful inrelation to their activity on the gastrointestinal tract. Alvimopan isparticularly useful in the prevention, inhibition and/or treatment ofileus resulting from abdominal surgery and, accordingly, is a preferreddrug for use in embodiments of the present invention. Alvimopan may beprovided, for example, in the form of a hot-melt gelatin capsule, whichpreferably comprises alvimopan suspended in water-soluble polyethyleneglycol. N-Methylnaltrexone may be useful in connection with embodimentsof the present invention that involve the prevention, inhibition and/ortreatment of opioid-induced constipation (OIC) and/or opioid-inducedbowel dysfunction (OBD).

The dosage of the drug that will be most suitable for use in the presentmethods will depend on a variety of factors including, for example, theparticular illness, disease or disorder which is being prevented,inhibited or treated, the particular active ingredient of the chosendrug, and the physiological characteristics of the particular patient.In certain embodiments involving mu opioid antagonist compounds,especially peripherally-acting mu opioid antagonist compounds, forexample, alvimopan or N-methylnaltrexone, the quantity of activeingredient in each dose that is delivered to a patient may varydepending upon various factors such as, for example, the pharmacodynamiccharacteristics of the particular agent and its mode and route ofadministration, the age, health and weight of the recipient, the natureand extent of the symptoms, the kind of concurrent treatment, thefrequency of treatment, and the effect desired. For example, in certainembodiments, the drug may be formulated for oral administration, whilein other embodiments, the drug may be formulated for parenteraladministration which includes, for example, administrationintravenously, intramuscularly, subcutaneously, intraocularly,intrasynovially, transepithelially including transdermally,ophthalmically, sublingually and buccally. A preferred form ofparenteral administration is intravenous administration. Generallyspeaking, oral administration may require higher dosages.

In certain preferred embodiments, including embodiments involvingperipheral mu opioid antagonist compounds, such as alvimopan, each dosemay be formulated for oral administration as described, for example, inU.S. Pat. No. 5,434,171, the disclosure of which is hereby incorporatedherein by reference, in its entirety. In accordance with suchembodiments, each dose delivered to the patient preferably contains fromabout 5 to about 20 mg of active ingredient (and all combinations andsubcombinations of ranges of amounts of active ingredient and specificamounts therein). More preferably, the peripheral mu opioid antagonistcompound is administered in a dose of from about 10 to about 15 mg, witha dose about 12 mg being even more preferred.

In other preferred embodiments, including embodiments involvingperipheral mu opioid antagonist compounds, such as alvimopan, each dosemay be formulated for parenteral administration, particularlyintravenous administration as described, for example, in copending U.S.application Ser. No. 11/143,535, filed Jun. 2, 2005, the disclosure ofwhich is hereby incorporated herein by reference, in its entirety. Inaccordance with such embodiments, each dose delivered to the patientpreferably contains from about 0.1 to about 6 mg of active ingredient(and all combinations and subcombinations of ranges of amounts of activeingredient and specific amounts therein). More preferably, theperipheral mu opioid antagonist compound is administered in a dose offrom about 0.5 to about 5 mg, with a dose of from about 1 mg to about 3mg being even more preferred.

In accordance with embodiments of the present invention, hospitals maybe provided with educational materials to ensure proper use, includingprescribing and dispensing of the drug. A wide variety of educationalmaterials may be employed to ensure proper prescribing and dispensingaccording to the methods described herein, including, for example,various forms of literature materials. The term “literature”, as usedherein, refers to a variety of materials including, for example, productinformation, educational brochures, continuing education monographs,videotapes and the like, and various combinations of two or more of suchmaterials. Depending on the nature and the type of the involvedmaterials, the literature may be paper-based or may be in electronicformat. In preferred embodiments, the literature may describe benefitsand/or risks associated with the drug, and may further includeinstructions for properly dispensing and administering the drug. Forexample, with regard to benefits, the literature may describe, forexample, advantageous medical benefits that may be realized by using theparticular drug, including the beneficial ameliorative or curativeproperties associated with ingesting the drug in connection with thetreatment, prevention or inhibition of a particular illness, diseaseand/or disorder. In addition to or instead of describing such benefits,the literature materials may describe possible disadvantageous aspectsassociated with the drug including, for example, undesirable observedadverse events, and the like, that may be associated with the drug orwhen the drug is used in certain ways such as, for example, when thedrug is used long-term. The term “observed adverse event”, as usedherein, refers to an observed consequence other than the one(s) forwhich a drug is used, especially on a tissue or organ system other thanthe one sought to be benefited by its administration. Examples ofadverse events within the context of the present invention include, forexample, ischemic cardiovascular events, such as myocardial infarctions.

Accordingly, in embodiments involving patients suffering from or who areexpected to suffer from gastrointestinal dysfunction, the literature maydescribe the preventive, ameliorative and/or curative properties of adrug, for example, a peripheral mu opioid antagonist compound, that maybe prescribed for the prevention, inhibition and/or treatment ofgastrointestinal dysfunction. In addition to, or instead of describingthe beneficial properties of the drug, the literature may describepossible disadvantageous properties, for example, the occurrence of oneor more adverse events that may have been observed with long-term use ofthe drug.

In preferred embodiments, the literature may take the form of, interalia, a hospital registration card or form which includes dispensing andadministration instructions. In preferred embodiments, the registrationcard or form may require that the hospital acknowledge that it hascomplied with aspects of the methods described herein. The registrationcard or form may also require that the hospital acknowledge that healthcare practitioners who are affiliated or associated with the hospital,and who are responsible, for example, for ordering, dispensing and/oradministering the drug, have complied with aspects of the presentmethods. For example, the registration card or form may require that thehospital acknowledge that it has received literature materials,including educational materials that describe the benefits and/or risksassociated with ingesting the drug. The registration card or form mayalso require that the hospital acknowledge that health carepractitioners affiliated or associated with the hospital have beenprovided the literature materials, including educational materials thatdescribe the benefits and/or risks of taking the drug.

Also in preferred embodiments, the registration card or form may requirethat the hospital acknowledge that it has measures in place to limit useof the drug to short-term use. The term “limit” or “limiting”, as usedherein in reference to using the drug short-term, generally means thatthere is a compliance rate of using the drug short-term of greater thanabout 50%. Preferably, the compliance rate is greater than about 55%,with a compliance rate of greater than about 60% being more preferred.Even more preferably, the compliance rate is greater than about 65%,with a compliance rate of greater than about 70% being still morepreferred. Yet more preferably, the compliance rate is greater thanabout 75%, with a compliance rate of greater than about 80% being stillmore preferred. In even more preferred embodiments, the compliance rateis greater than about 85%, with a compliance rate of greater than about90% being yet more preferred. Still more preferably, the compliance rateis greater than about 95%. In particularly preferred embodiments, a drugmay be delivered or administered to hospital patients for substantiallycomplete short-term use (i.e., nearly or up to a 100% compliance rate).

The measures that a hospital preferably has in place to limit use of thedrug to short-term use may take a variety of forms. Preferably, themeasures are in the form of systems, order sets, protocols, guidelinesor the like. The term “system”, as used herein, refers to acomprehensive, integrated information system designed to manage, interalia, clinical aspects within a hospital, and may encompass paper-basedinformation processing as well as data processing machines, and may becomposed of one or more software components with specialty-specificextensions as well as a large variety of sub-systems in medicalspecialties. The term “order set”, as used herein, refers to a set ofstandardized instructions for the management of a particular disease,condition, or procedural intervention, presented as a group of orders tobe individually selected and signed by an authorized prescriber. Theterm “protocol”, as used herein, refers to a step-by-step statement of aprocedure routinely used in the care of individual patients to assurethat the intended effect is reliably achieved. The term “guideline”, asused herein, refers to an evidence-based statement of best practice inthe prevention, diagnosis, or management of a given symptom, disease, orcondition for individual patients under normal circumstances. Othertypes of measures that may be employed to limit use of the drug toshort-term use, and to minimize long-term use of the drug, will beapparent to one of ordinary skill in the art, once armed with theteachings of the present application. Thus, in accordance with themethods of the present invention, measures are preferably put in placethat ensure that the delivery and administration of the drug is limitedto short-term use, and also ensure that long-term use of the drug isminimized.

With further reference to literature provided to the hospitals, theregistration card or form may also preferably require that the hospitalacknowledge that the drug will not be dispensed for outpatient use, andmay further require that the hospital acknowledge that the drug will notbe transferred to hospitals that are not in full compliance with themethods as described herein. The hospital will preferably complete theregistration card or form by providing information requested therein.Information which may be requested of the hospital in the registrationcard or form may include, for example, the hospital's name, thehospital's identification number, the hospital's address, the identityof the person that has been authorized to fill out the form on thehospital's behalf, and the like. The registration card or form willpreferably be returned to an authorized recipient of the registrationmaterials such as, for example, the manufacturer or distributor of thedrug, by an appropriate means of transmission, for example, by mail,facsimile transmission or on-line transmission.

Once the registration card or form is returned, the authorized recipientmay identify which hospitals are eligible to treat the patients. Forexample, in embodiments involving acute care patients, such as abdominalsurgery patients, particularly bowel resection surgery patients, theauthorized recipient may determine whether the hospital is an acute carehospital, including whether the hospital and the health carepractitioners therein perform abdominal surgery, including bowelresection surgery. Accordingly, it may be possible to identify fromamong the entire population of hospitals that have filled out andreturned a registration card or form, a subpopulation of suitablehospitals. The hospitals in the subpopulation are preferably those whichtreat the patients (e.g., hospitals which perform surgery, such asabdominal surgery, particularly bowel resection surgery) and which havemeasures in place to limit the use of the drug to short-term use,in-hospital use, or short-term in-hospital use and thus minimizelong-term use or out-patient use of the drug. Hospitals which do notfill out and return a registration card or form, or which return a cardthat is incompletely filled out, are not included in the subpopulation.

In accordance with the methods of the present invention, thesubpopulation of hospitals is preferably registered in a storage mediumsuch as, for example, a paper-based storage medium or a computerreadable storage medium. Suitable paper-based or computer readablestorage media which may be employed for registration of the hospitalswill be apparent to one of ordinary skill in the art, once armed withthe teachings of the present application. The listing of thesubpopulation of hospitals is maintained, for example, by the authorizedrecipient, or by an entity that has been authorized to maintain thelisting on behalf of the authorized recipient. Hospitals that areincluded in the subpopulation, and that are listed in the storagemedium, may refer to the listing to conveniently identify otherhospitals within the subpopulation. Similarly, the manufacturer ordistributor of the drug or other authorized entity, for example, anentity that is authorized to ship drug product, may also refer to thelisting to identify hospitals within the subpopulation.

Once registered in the storage medium, the hospitals in thesubpopulation may be authorized to receive shipment of the drug. Afterreceiving shipment of the drug, the drug may be prescribed and dispensedto the patient at the desired doses and administration frequencies, asdiscussed above. In certain embodiments of the invention, the methodsmay further involve observing and/or monitoring the patient for thepossible occurrence of an observed adverse event while the patient isreceiving the drug.

In certain embodiments of the invention, hospitals in the subpopulationmay transfer the drug to one or more additional hospitals for deliveryto patients within the additional hospitals. Such transfer of the drugmay occur provided that the one or more additional hospitals are alsoregistered in the storage medium, i.e., the additional hospitals havesatisfied the conditions described above to be included in thesubpopulation of hospitals. If this condition is met, then the drug maybe transferred to the additional hospitals, and the drug may bedispensed to patients in such additional hospitals for short-term use.

When ranges are used herein, all combinations and subcombinations ofranges and specific embodiments therein are intended to be included.

The disclosures of each patent, patent application, and publicationcited or described in this document are hereby incorporated herein byreference, in their entirety.

Those skilled in the art will appreciate that numerous changes andmodifications can be made to the preferred embodiments of the inventionand that such changes and modifications can be made without departingfrom the spirit of the invention. It is, therefore, intended that theappended claims cover all such equivalent variations as fall within thetrue spirit and scope of the invention.

1. A method for delivering alvimopan to hospital patients for short-termuse wherein the method comprises: identifying hospitals that may beeligible to dispense alvimopan, said eligibility requiring that saidhospitals: perform abdominal surgery or are acute care hospitals; andtreat patients who are inpatients undergoing bowel resection surgeryinvolving anastomosis; providing said identified hospitals withliterature regarding use of alvimopan including dosing recommendationsand contraindications, and which describes the observation of an adverseevent associated with long-term use of alvimopan; wherein alvimopan isformulated for oral administration; receiving registration informationfrom said identified hospitals; identifying a subpopulation of saididentified hospitals which treat the patients and which have saidmeasures in place to limit use of alvimopan to short-term use; whereinsaid measures comprise systems, order sets or protocols to limit use ofalvimopan to short-term use; registering said subpopulation in acomputer readable storage medium; authorizing said subpopulation toreceive shipment of alvimopan; and dispensing alvimopan to the patientsin said subpopulation for short-term use; wherein the patients arehospital inpatients and the delivery is limited to in-hospitaladministration; and monitoring the patients for said observed adverseevent.
 2. A method according to claim 1 wherein the short term usecomprises the delivery to each of the patients of no more than about 15doses of alvimopan.
 3. A method according to claim 2 wherein the drug isdelivered to said bowel resection surgery patients both prior to andafter surgery.
 4. A method according to claim 3 wherein the drug isdelivered to said bowel resection surgery patients for no more thanabout 7 days after surgery.
 5. A method according to claim 4 whereinabout 1 dose of the drug is delivered to each of said bowel resectionsurgery patients prior to surgery.
 6. A method according to claim 5wherein each of said doses contains about 12 mg alvimopan.
 7. A methodaccording to claim 1 further comprising the step of: transferringalvimopan from a hospital in said subpopulation to one or moreadditional hospitals for delivery to a patient within said one or moreadditional hospitals, provided that: (i) said one or more additionalhospitals are eligible to dispense alvimopan; and (ii) said one or moreadditional hospitals have been provided with the literature regardinguse of alvimopan; including dosing recommendations andcontraindications, and which describes the observation of an adverseevent associated with long-term use of alvimopan; registering said oneor more additional hospitals in the computer readable storage medium;and authorizing said one or more additional hospitals to receiveshipment of alvimopan.
 8. A method according to claim 7 furthercomprising the step of dispensing the drug to said patients in said oneor more additional hospitals for short-term use.